Results 31 to 40 of about 1,385,084 (219)

Partial Deletion of Glycoprotein B5R Enhances Vaccinia Virus Neutralization Escape while Preserving Oncolytic Function

open access: yesMolecular Therapy: Oncolytics, 2019
Vaccinia virus (VV) has been utilized in oncolytic virotherapy, but it risks a host antiviral immune response. VV has an extracellular enveloped virus (EEV) form consisting of a normal virion covered with a host-derived outer membrane that enables its ...
Motomu Nakatake   +9 more
doaj   +1 more source

Dependency of EGFR activation in vanadium-based sensitization to oncolytic virotherapy

open access: yesMolecular Therapy: Oncolytics, 2022
Oncolytic virotherapy is a clinically validated approach to treat cancers such as melanoma; however, tumor resistance to virus makes its efficacy variable. Compounds such as sodium orthovanadate (vanadate) can overcome viral resistance and synergize with
Boaz Wong   +6 more
doaj   +1 more source

Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1

open access: yesMolecular Therapy: Oncolytics, 2019
The efficacy of immune checkpoint blockade therapy against immunologically “cold” tumors can be enhanced by applying the checkpoint inhibitors in combination with oncolytic viruses.
Yujie Zhu   +9 more
doaj   +1 more source

Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors

open access: yesFrontiers in Cellular and Infection Microbiology, 2022
Oncolytic virus therapy has advanced rapidly in recent years. Natural or transgenic viruses can target tumor cells and inhibit tumor growth and metastasis in various ways without interfering with normal cell and tissue function.
Qingbo Li   +9 more
doaj   +1 more source

Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect [PDF]

open access: yes, 2017
: With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits.

core   +1 more source

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators

open access: yesBiomedicines, 2020
As a live biologic agent, oncolytic vaccinia virus has the ability to target and selectively amplify at tumor sites. We have previously reported that deletion of thymidine kinase and ribonucleotide reductase genes in vaccinia virus can increase the ...
Franck Gallardo   +14 more
doaj   +1 more source

Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma

open access: yesFrontiers in Immunology, 2023
Recurrent glioma treatment is challenging due to molecular heterogeneity and treatment resistance commonly observed in these tumors. Researchers are actively pursuing new therapeutic strategies.
Mingming Hu   +7 more
doaj   +1 more source

Cell cycle progression or translation control is not essential for vesicular stomatitis virus oncolysis of hepatocellular carcinoma. [PDF]

open access: yes, 2010
The intrinsic oncolytic specificity of vesicular stomatitis virus (VSV) is currently being exploited to develop alternative therapeutic strategies for hepatocellular carcinoma (HCC). Identifying key regulators in diverse transduction pathways that define
Enrico N. De Toni   +32 more
core   +2 more sources

IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity

open access: yesMolecular Therapy: Oncolytics, 2022
Oncolytic virotherapies have shown excellent promise in a variety of cancers by promoting antitumor immunity. However, the effects of oncolytic virus-mediated type I interferon (IFN-I) production on antitumor immunity remain unclear.
Nader El-Sayes   +6 more
doaj   +1 more source

Key parameters of measles virus production for oncolytic virotherapy [PDF]

open access: yes, 2012
Attenuated measles virus has revealed selective tumor cell killing and is currently tested in clinical trials for the therapy of cancer patients. The amount of infectious particles per dose needed for oncolytic therapy can be more than a million times ...
Salzig, Denise   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy